Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKesson
Covington
Chubb
Express Scripts

Generated: March 21, 2019

DrugPatentWatch Database Preview

ATOVAQUONE - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for atovaquone and what is the scope of atovaquone freedom to operate?

Atovaquone is the generic ingredient in five branded drugs marketed by Amneal Pharms, Apotex Inc, Glenmark Pharms, Hetero Labs Ltd Iii, Lupin Ltd, Paddock Llc, Glaxosmithkline Llc, Glenmark Generics, Mylan Pharms Inc, and Glaxosmithkline, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for atovaquone. Seven suppliers are listed for this compound.

Pharmacology for ATOVAQUONE
Medical Subject Heading (MeSH) Categories for ATOVAQUONE
Synonyms for ATOVAQUONE
1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-
1,4-Naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-, trans-
1,4-Naphthalenedione, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-
1,4-Naphthalenedione, 2-[cis-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-
1,4-Naphthalenedione, 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy
1,4-naphthalenedione,2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-
137732-39-9
2-((1r,4r)-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione
2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-nap
2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
2-(TRANS-4-(4-CHLOROPHENYL)CYCLOHEXYL)-3-HYDROXY-1,4-NAPHTHALENEDIONE
2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione
2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexy]-3-hydroxy-1,4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-dihydronaphthalene-1,4-dione
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-napthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1.4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-naphthalene-1,4-dione
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione
2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxynaphthoquinone, trans-
2-[trans-4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione
2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione
2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
2-Hydroxy-3-[4-(4-chlorophenyl)cyclohexyl]-1,4-naphthoquinone
233A184
3-[4-(4-Chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthalenedione
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxy-naphthalene-1,2-dione
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione
3-[4-(p-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthoquinone
566C
566C80
78668-EP2307343A1
94015-53-9
95233-18-4
AB00053222_04
AB00053222_05
AB00053222-03
AB0012456
AB00513855
AB0107187
AB0211463
AC-30251
AC1L2MZG
AC1Q6E9K
Acuvel
AK544285
AKOS005567953
AKOS015895691
AKOS015961933
AN-6439
AS-12809
Atavaquone
ATO & IL-12
Atovaquone (Atavaquone)
Atovaquone (JAN/USP/INN)
Atovaquone [USAN:BAN:INN]
Atovaquone [USAN:USP:INN:BAN]
Atovaquone & Interleukin 12
Atovaquone EP Impurity B
ATOVAQUONE-D4
Atovaquone, >=98% (HPLC)
BC208879
BCP09477
BDBM192009
BIDD:GT0849
BPBio1_000603
BSPBio_000547
BSPBio_002681
BW 566C
BW 566C-80
BW 566C80
BW-556C-80
BW-566C
BW-566C-80
BW-A 566C
C06835
C22H19ClO3
CAS-95233-18-4
CCG-220534
CCG-39090
CHEBI:575568
CHEBI:95346
CHEMBL222334
CHEMBL519462
Cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
cis-Atovaquone
CRL-8131 & Atovaquone
CS-2702
CTK5H7581
D00236
DB01117
DivK1c_006782
DRG-0084
DSSTox_CID_2629
DSSTox_GSID_22629
DSSTox_RID_76664
DTXSID7022629
FD7252
FT-0081084
FT-0602868
GTPL9695
HMS1569L09
HMS1922F19
HMS2089M14
HMS2093C10
HMS2096L09
HMS2235N08
HMS3369N09
HMS3651N20
HMS3713L09
HSDB 7083
HY-13832
I06-0872
J90007
KB-270797
KBio1_001726
KBio2_002223
KBio2_004791
KBio2_007359
KBio3_001901
KBioGR_001594
KBioSS_002223
KS-00000FO3
KUCQYCKVKVOKAY-CTYIDZIISA-N
KUCQYCKVKVOKAY-OTVXOJSOSA-N
KUCQYCKVKVOKAY-UHFFFAOYSA-N
LS-178256
MCULE-7318126574
Mepron
Mepron (antipneumocystic)
Mepron (TN)
MLS002153863
MolPort-003-666-542
MolPort-006-167-710
NAP016
NCGC00016961-01
NCGC00016961-02
NCGC00016961-03
NCGC00016961-04
NCGC00016961-06
NCGC00016961-07
NCGC00095113-01
NCGC00095113-02
NSC-759582
NSC759582
Pharmakon1600-01504210
Prestwick0_000534
Prestwick1_000534
Prestwick2_000534
Prestwick3_000534
s3079
SBI-0052893.P002
SC-15688
SC-21393
SCHEMBL1542719
SCHEMBL1649508
SCHEMBL21694
SCHEMBL21695
SCHEMBL637069
SCHEMBL9975142
SCHEMBL9975229
SMR001233220
SPBio_001849
SPBio_002468
SpecPlus_000686
Spectrum_001743
SPECTRUM1504210
Spectrum2_001665
Spectrum3_000991
Spectrum4_001117
Spectrum5_001382
SR-05000001438
SR-05000001438-1
SR-05000001438-2
SR-05000001438-4
SR-05000001438-5
STK636160
SW219222-1
Tox21_110714
Tox21_110714_1
trans-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione
trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
TX-010638
UNII-Y883P1Z2LT
Wellvone
Y883P1Z2LT
Z1541632806
ZINC100017856
ZINC100345537
ZINC116473771
ZINC12504271
ZINC299873031

US Patents and Regulatory Information for ATOVAQUONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd ATOVAQUONE atovaquone SUSPENSION;ORAL 209105-001 Sep 11, 2018 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 202362-001 May 27, 2014 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Paddock Llc ATOVAQUONE atovaquone SUSPENSION;ORAL 207833-001 Apr 28, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ATOVAQUONE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc MEPRON atovaquone TABLET;ORAL 020259-001 Nov 25, 1992 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc MEPRON atovaquone TABLET;ORAL 020259-001 Nov 25, 1992 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc MEPRON atovaquone SUSPENSION;ORAL 020500-001 Feb 8, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Daiichi Sankyo
US Department of Justice
Baxter
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.